NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

This roundtable series explores biomarker testing and targeted therapy for patients with grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH 2 mutations, as discussed by key opinion leaders at virtual live events and interviews.

Targeted Inhibition for Grade 2 IDH-Mutant Glioma

Defining Brain Tumor Progression: Balancing Clinical Symptoms and Imaging

Defining Brain Tumor Progression: Balancing Clinical Symptoms and Imaging

Experts explain how MRI trends, seizures, and spectroscopy guide when IDH-mutant glioma monitoring ends and radiation or chemo begins.

Experts Discuss Evolving Paradigms in Glioma Treatment

Experts Discuss Evolving Paradigms in Glioma Treatment

February 19, 2026

During a Case-Based Roundtable event, Timothy Cloughesy, MD, and participants discuss targeted IDH inhibition in patients with grade 2 gliomas.

Ongoing Trials Could Expand Role of IDH Inhibitors in Resected Glioma

Ongoing Trials Could Expand Role of IDH Inhibitors in Resected Glioma

January 07, 2026

During a live event, Jan Drappatz, MD, and participants discussed which patients with glioma should receive IDH inhibitors and what next steps could identify who will benefit.

Oncologists Discuss IDH Inhibition Vs Chemo + RT for Grade 2 Glioma

Oncologists Discuss IDH Inhibition Vs Chemo + RT for Grade 2 Glioma

December 11, 2025

During a live event, Jan Drappatz, MD, surveyed participants on the rationale for their choice of treatment for a 39-year-old patient with grade 2 astrocytoma.